Theraphage is at the forefront of developing and producing bacteriophage immunotherapeutics. The company collaborates with researchers from the University of Waterloo to create a COVID-19 vaccine that can be administered intranasally. This innovative approach leverages bacteriophages, which are viruses that infect bacteria, to provide a safe and simplified therapeutic strategy. Theraphage's dual approach platform combines phage display strategies with gene delivery mechanisms to ensure targeted and effective therapies. The company operates in the biotechnology sector, primarily serving healthcare providers and research institutions. Its business model revolves around research and development, partnerships, and licensing agreements, generating revenue through the commercialization of its therapeutic solutions. Theraphage's interdisciplinary team includes students, professors, and industry leaders, all working together to advance the field of bacteriophage therapy.

Keywords: bacteriophage, immunotherapeutics, COVID-19, intranasal vaccine, biotechnology, gene delivery, phage display, healthcare, research, interdisciplinary.